Date: 31st July, 2026

Corporate Overview

Balaxi Pharmaceuticals Limited (CIN: L25191TG1942PLC121598) was incorporated in 1942. The registered office and corporate address is at 3rd Floor, Elegance Tower, Mathura Road, Jasola, New Delhi - 110025. Contact email: secretarial@balaxi.in, telephone: +91 40 2355 5300, website: www.balaxipharma.in. The reporting financial year is April 2025-March 2026. Paid-up capital is ₹5,15,00,000 (Five Crore and Fifteen Lakh Only). Mr. Aman Purohit, Company Secretary and Compliance Officer (ICSI Membership No.: A59345) is the designated contact for BRSR queries.

Business Activities

  • Reporting Boundary: Standalone basis
  • Main Business Activity: International Wholesale trading/distribution (100% of turnover)
  • Products: Pharmaceutical Products (100% of turnover, NIC Code: 464)
  • Export Contribution: 100% of total turnover
  • Business Model: Asset-light model with no capital expenditure incurred during FY 2025-26

Employee Statistics

Permanent Employees (Total: 62)

  • Male: 51 employees (82.26%)
  • Female: 11 employees (17.74%)

Permanent Workers (Total: 7)

  • Male: 6 workers (85.71%)
  • Female: 1 worker (14.29%)

Gender Representation

  • Board of Directors: 33.33% women (2 out of 6 directors)
  • Key Management Personnel: 0% women (0 out of 4 KMPs)

Employee Turnover Rates (FY 2026)

  • Permanent Employees: 35.08% overall turnover rate
  • Permanent Workers: 125% turnover rate

Subsidiary Information

Wholly-owned subsidiaries:

1. Balaxi Overseas Private Limited (Holding Company, owns 63.40% of equity)

2. Balaxi Global FZCO, Dubai (Wholly owned subsidiary, 100%)

Step-down subsidiaries (100% owned by Balaxi Global FZCO):

  • Republic of Guatemala
  • Dominican Republic
  • DE., El Salvador
  • Angola

Changes during FY 2025-26:

  • Balaxi Healthcare Centrafrique, SARL struck off effective 10th April, 2025
  • Balaxi Healthcare Nicaragua acquired effective 1st April, 2025

Material Responsibility Issues

The company identified three material responsible business conduct issues:

1. Carbon Footprint in Global Supply Chain (Risk): Climate change may lead to stricter environmental regulations increasing transportation costs. The company is ensuring vendors/CDMOs comply with applicable environmental standards.

2. Diversity and Inclusion (Opportunity): Fostering diverse and inclusive workplace that promotes equality and non-discrimination to build a good talent pool.

3. Corporate Governance (Opportunity): Ensuring good governance and transparent practices to generate investor interest and improved financial performance.

Policy Framework

The company has policies covering all nine SEBI Business Responsibility Principles (P1-P9) extending to value chain partners. Policies are available at https://balaxipharma.in/corporate-policies and include:

  • Anti Bribery and Anti Corruption Policy
  • Grievance Redressal Mechanism
  • Equal Opportunity Policy

Certifications obtained:

  • Certificate of Consent for Establishment (Orange Category) from Telangana State Government
  • Petroleum and Explosives Safety Organisation (PESO) certification

Training and Awareness

Percentage coverage by training programs:

  • Board of Directors: 100% trained on Anti Bribery and Anti Corruption Policy
  • Key Managerial Personnel: 100% trained on Anti Bribery and Anti Corruption Policy
  • Other Employees: 100% trained on Anti Bribery and Anti Corruption Policy and Grievance Redressal Mechanism

Compliance Status

  • No fines/penalties/settlement amounts paid in proceedings with regulators/law enforcement agencies
  • No appeals/revisions pending
  • No complaints regarding conflict of interest for directors, KMPs, or employees
  • No complaints of corruption
  • 95 grievances received and redressed in FY 2025-26

ESG Performance Indicators

Employee Well-being

  • Cost incurred on well-being measures: ₹2,95,100/-
  • Retirement benefits coverage: PF (100%), Gratuity (100%), ESI (71.42%)
  • Office accessible to differently abled employees
  • Equal opportunity policy implemented

Environmental Performance

  • Total electricity consumption: 1391.82 units (FY 2026)
  • Water withdrawal: 2962 KL from third party sources (FY 2026)
  • Greenhouse gas emissions: Not applicable (company not in manufacturing)
  • Waste management: Validation batches handled with authorized contractors for ETP waste disposal

Social Performance

  • 100% employees covered under well-being programs
  • 100% employees covered under performance management system
  • Women safety programs, road safety programs, and self-defense programs conducted
  • Fire emergency training conducted

Stakeholder Engagement

The company maintains engagement with:

  • Customers (Distributors, Wholesalers, Retailers) through satisfaction surveys and media
  • Suppliers/CDMOs through regular interactions and meetings
  • Employees through trainings, development programs, and engagement initiatives
  • Investors through AGMs, presentations, conference calls, and meets
  • Government/regulators through meetings and formal filings
  • Community through CSR partnerships

Certifications and Memberships

  • Pharmexcil Registration from Pharmaceuticals Export Promotion Council of India
  • FSSAI Certification from Food Safety and Standards Authority of India
  • APEDA Certification from Agricultural and Processed Food Products Export Development Authority
  • Member of Federation of Indian Export Organisation (FIEO)

Governance Structure

  • Highest authority for BRSR implementation: Director (contact: +91 40 23555300, secretarial@balaxi.in)
  • Specified Committee: Managing Director as Chairman with other functional heads
  • Internal mechanisms for grievance redressal comprising Internal Resolution Committee

No material disclosures under: Financial Results, Dividend Declaration, Board Meeting Outcomes, Auditor's Report, Disinvestment/Strategic Actions, Media Release/Investor Communication sections.